Logo image of MRKR

MARKER THERAPEUTICS INC (MRKR) Stock Fundamental Analysis

NASDAQ:MRKR - Nasdaq - US57055L2060 - Common Stock - Currency: USD

1.57  -0.06 (-3.68%)

Fundamental Rating

2

Overall MRKR gets a fundamental rating of 2 out of 10. We evaluated MRKR against 571 industry peers in the Biotechnology industry. The financial health of MRKR is average, but there are quite some concerns on its profitability. MRKR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MRKR had negative earnings in the past year.
MRKR had a negative operating cash flow in the past year.
MRKR had negative earnings in each of the past 5 years.
MRKR had a negative operating cash flow in each of the past 5 years.
MRKR Yearly Net Income VS EBIT VS OCF VS FCFMRKR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M

1.2 Ratios

MRKR's Return On Assets of -88.88% is on the low side compared to the rest of the industry. MRKR is outperformed by 71.40% of its industry peers.
Looking at the Return On Equity, with a value of -130.17%, MRKR is doing worse than 61.28% of the companies in the same industry.
Industry RankSector Rank
ROA -88.88%
ROE -130.17%
ROIC N/A
ROA(3y)-65.5%
ROA(5y)-61.14%
ROE(3y)-102.17%
ROE(5y)-92.03%
ROIC(3y)N/A
ROIC(5y)N/A
MRKR Yearly ROA, ROE, ROICMRKR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400

1.3 Margins

MRKR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRKR Yearly Profit, Operating, Gross MarginsMRKR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K

More info and screens

5

2. Health

2.1 Basic Checks

MRKR does not have a ROIC to compare to the WACC, probably because it is not profitable.
MRKR has more shares outstanding than it did 1 year ago.
MRKR has more shares outstanding than it did 5 years ago.
MRKR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MRKR Yearly Shares OutstandingMRKR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
MRKR Yearly Total Debt VS Total AssetsMRKR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

MRKR has an Altman-Z score of -55.72. This is a bad value and indicates that MRKR is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -55.72, MRKR is not doing good in the industry: 94.85% of the companies in the same industry are doing better.
MRKR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -55.72
ROIC/WACCN/A
WACC9.44%
MRKR Yearly LT Debt VS Equity VS FCFMRKR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 3.15 indicates that MRKR has no problem at all paying its short term obligations.
MRKR has a Current ratio of 3.15. This is in the lower half of the industry: MRKR underperforms 63.06% of its industry peers.
A Quick Ratio of 3.15 indicates that MRKR has no problem at all paying its short term obligations.
MRKR's Quick ratio of 3.15 is on the low side compared to the rest of the industry. MRKR is outperformed by 61.28% of its industry peers.
Industry RankSector Rank
Current Ratio 3.15
Quick Ratio 3.15
MRKR Yearly Current Assets VS Current LiabilitesMRKR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for MRKR have decreased by -0.14% in the last year.
Looking at the last year, MRKR shows a decrease in Revenue. The Revenue has decreased by -2.95% in the last year.
The Revenue has been growing by 73.60% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-0.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.92%
Revenue 1Y (TTM)-2.95%
Revenue growth 3Y91.7%
Revenue growth 5Y73.6%
Sales Q2Q%640.77%

3.2 Future

MRKR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.64% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y80.85%
EPS Next 2Y14.83%
EPS Next 3Y6.22%
EPS Next 5Y13.64%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MRKR Yearly Revenue VS EstimatesMRKR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M
MRKR Yearly EPS VS EstimatesMRKR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -50 -100 -150 -200 -250

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MRKR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MRKR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRKR Price Earnings VS Forward Price EarningsMRKR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRKR Per share dataMRKR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.83%
EPS Next 3Y6.22%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRKR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MARKER THERAPEUTICS INC

NASDAQ:MRKR (2/21/2025, 8:00:01 PM)

1.57

-0.06 (-3.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)03-24 2025-03-24/amc
Inst Owners41.79%
Inst Owner Change-95.38%
Ins Owners2.56%
Ins Owner Change2.93%
Market Cap16.81M
Analysts85.71
Price Target11.73 (647.13%)
Short Float %2.41%
Short Ratio2.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)38.82%
Min EPS beat(2)34.64%
Max EPS beat(2)43%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-39.47%
PT rev (3m)-26.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)38.12%
EPS NY rev (3m)54.48%
Revenue NQ rev (1m)425%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)79.6%
Revenue NY rev (3m)117.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.12
P/FCF N/A
P/OCF N/A
P/B 2.26
P/tB 2.26
EV/EBITDA N/A
EPS(TTM)-1.08
EYN/A
EPS(NY)-2.36
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.5
BVpS0.7
TBVpS0.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -88.88%
ROE -130.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.5%
ROA(5y)-61.14%
ROE(3y)-102.17%
ROE(5y)-92.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.15
Quick Ratio 3.15
Altman-Z -55.72
F-Score3
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.92%
EPS Next Y80.85%
EPS Next 2Y14.83%
EPS Next 3Y6.22%
EPS Next 5Y13.64%
Revenue 1Y (TTM)-2.95%
Revenue growth 3Y91.7%
Revenue growth 5Y73.6%
Sales Q2Q%640.77%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y72.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.4%
OCF growth 3YN/A
OCF growth 5YN/A